Dopamine/Noradrenaline Reuptake Inhibitor (DNRI) — Smoking Cessation
Pregnancy: Avoid unless essential — limited data
Bupropion (Smoking Cessation)
Brand names: Zyban
Adult dose
Dose: 150 mg OD × 6 days, then 150 mg BD (minimum 8h between doses). Duration 7–9 weeks.
Route: Oral (swallow whole — do not crush)
Frequency: OD for 6 days, then BD
Max: 300 mg/day
Set quit date for week 2 of treatment (continue smoking during first week). Lowers seizure threshold — avoid in patients with seizure risk. Last dose no later than 6pm to prevent insomnia.
Paediatric dose
Route: N/A
Frequency: N/A
Max: Not licensed in children
Not applicable in paediatric patients
Dose adjustments
Renal
Reduce dose — 150 mg OD throughout in renal impairment
Hepatic
Reduce dose — 150 mg OD throughout in hepatic impairment
Clinical pearls
- Smoking cessation: start 1 week before quit date — drug takes time to reach therapeutic levels
- Seizure risk: dose-dependent; avoid doses >150 mg in at-risk patients; take last dose before 6pm to limit peak levels
- Useful in patients with depression and smoking — dual benefit (antidepressant at higher doses)
- Available as varenicline for smoking cessation — may be more effective but review psychiatric history first
Contraindications
- Epilepsy or seizure history
- Eating disorders (anorexia/bulimia — seizure risk)
- Bipolar disorder
- Abrupt alcohol/benzodiazepine withdrawal (seizure risk)
- MAOIs within 14 days
Side effects
- Insomnia (common — take last dose before 6pm)
- Dry mouth
- Headache
- Nausea
- Agitation
- Seizures (dose-related — 0.1% at 300 mg/day)
- Hypertension
Interactions
- MAOIs — seizures/serotonin syndrome (contraindicated)
- Antipsychotics/TCAs — lower seizure threshold (additive)
- Tamoxifen — bupropion reduces tamoxifen activation (CYP2D6 inhibition)
Monitoring
- Seizure risk assessment before starting
- Blood pressure (baseline and periodic)
- Mood changes
- Insomnia
- Smoking cessation status at 4 and 8 weeks
Reference: BNFc; BNF; NICE PH10 Smoking Cessation; Zyban SPC. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF